FGFR2 fusions and rearrangements occur in up to 10-15% of intrahepatic cholangiocarcinomas (iCCA) and alterations in FGFR3 occur in 15-30% of urothelial cancers. The clinical benefit from currently ...

Fibroblast growth factor receptors (FGFRs; FGFR1, FGFR2, FGFR3, FGFR4) are frequently mutated oncogenes in solid cancers. The oncogenic potential of FGFR rearrangements and few hotspot point mutations ...

FGFR2 gene fusion is observed in approximately 14% of intrahepatic cholangiocarcinoma, which accounts for 15%-30% of all biliary tract cancers, according to Eisai, but drug options are limited.

Cogent Biosciences, a biotechnology company specializing in precision therapies, has secured a debt financing facility of up to $400 million with SLR Capital Partners to support its growth and the ...

Eli Lilly has opened up a second market for its new Alzheimer's disease therapy Kisunla, after Japan followed the US in approving the drug.

Here, the authors show that inhibition of FGFR2 could induce necroptosis via crosstalk between the NF2-Hippo-YAP and RIP1-MST1-MLKL pathways and shapes an immunosuppressive tumor microenvironment.

Conditional ablation of Fgfr2 in the prostate epithelium compromises prostate development (Lin et al., 2007). Unlike the normal prostate that composed of 4 pairs of anterior, dorsal, lateral, and ...

The firm will assess irpagratinib plus best supportive care in patients with FGF19-overexpressing advanced liver cancer.

Andrew Robbins, President and CEO of Cogent Biosciences, expressed enthusiasm about the strategic financing, emphasizing that ...